In this issue:
Lenalidomide maintenance after autologous SCT in mantle cell lymphoma
Gemtuzumab ozogamicin + chemotherapy in relapsed AML after allogenic SCT
Imetelstat achieves transfusion independence in lower-risk MDS
Venetoclax + rituximab in relapsed CLL
R-CHOP + lenalidomide for MYC rearranged large B-cell lymphoma
GDP-ML regimen for newly diagnosed extranodal NK/T-cell lymphoma, nasal type
Mavorixafor for WHIM syndrome
Zanubrutinib for MYD88 wild-type Waldenström macroglobulinaemia
Recommended pacritinib dose for advanced myelofibrosis
Midostaurin + chemotherapy in AML with high FLT3-ITD allelic ratio
Please login below to download this issue (PDF)